Improved Overall Survival Among Newly Diagnosed Aggressive Adult T-Cell Leukemia/Lymphoma Patients Treated with Mogamulizumab Plus EPOCH Compared to Mogamulizumab Plus Vcap-AMP-Vecp

Tatsuro Jo(Japanese Red Cross Society, Japan), Kazuto Shigematsu(Japanese Red Cross Society, Japan), Kaori Matsuzaka(Japanese Red Cross Society, Japan), Haruna Shioya(Japanese Red Cross Society, Japan), Takahiro Sakai(Japanese Red Cross Society, Japan), Masatoshi Matsuo(Japanese Red Cross Society, Japan), Hiro-o Tominaga(Japanese Red Cross Society, Japan), Shizuka Hayashi(Japanese Red Cross Society, Japan), Yohei Kaneko(Japanese Red Cross Society, Japan), Jun Taguchi(Japanese Red Cross Society, Japan)
Blood
November 13, 2019
Cited by 1


Related Papers